Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that ...
Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and ...
Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that ...
To maximize our targeting efficiency of MG in the adult mouse retina, we delivered proneural genes using the AAV.7m8 vector, which was shown to be potent when delivered through the vitreous in vivo ...
Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is designed to be administered as a one-time ...
The gene therapy uses a proprietary adeno-associated virus (AAV) vector capsid, AAV.7m8, to deliver a coding sequence for the aflibercept protein. There are multiple other gene therapies in late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback